Skip to content

COMPARISON OF OUTCOME OF INTRAVENOUS MIDAZOLAM INFUSION VERSUS INTRAVENOUS INFUSION OF SODIUM VALPROATE IN THE TREATMENT OF STATUS EPILEPTICUS IN CHILDREN AT A TERTIARY CARE HOSPITAL.

COMPARISON OF OUTCOME OF INTRAVENOUS MIDAZOLAM INFUSION VERSUS INTRAVENOUS INFUSION OF SODIUM VALPROATE IN THE TREATMENT OF STATUS EPILEPTICUS IN CHILDREN AT A TERTIARY CARE HOSPITAL.

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20231115003
Enrollment
45
Registered
2023-11-15
Start date
2023-12-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

EPILEPSY DRUGS EPILEPSY DRUGS

Interventions

after group allotment in group a will give initial dose of midazolam 0.2 mg per kg up to 10 mg. we will start midazolam infusion at 1 mcg per kg per minute and increase by 1 mcg per minute every 5 m
Experimental Drug
efficacy of midazolam and sodium valproate

Sponsors

University of Health Sciences Lahore,pakistan
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 14 Years

Inclusion criteria

Inclusion criteria: All children presenting with status epilepticus with duration > 5 minutes. Failure of first and second line antiepileptics age group 2 to 14 years

Exclusion criteria

Exclusion criteria: All children with diagnosed muscular dystrophies on clinical examination. severe hypotension(according to age ) severe atrial or ventricular block(on ecg) metabolic diseases (hypoglycemia, hypocalcemia, hypomagnesemia, hyponatremia, hypenatremia, uremicencephalophaty, hepaticencephlopathy). History of use of anticonvulsants before presenting to hospital. Renal or Hepatic diseases on medical records and relevant investigations.

Design outcomes

Primary

MeasureTime frame
Efficacy 24 hours It will be determined in terms of complete cessation of seizures within 30 minutes of initiation of therapy and absence of seizure recurrence after completing the last dose of anticonvulsant.

Secondary

MeasureTime frame
NA NA NA

Countries

Pakistan

Contacts

Public Contactshahid latif

University of Health Sciences Lahore

shahid_ch_89@yahoo.com923008808157

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026